Harvard Bioscience Announces Appointment of Susan Steele to Board of Directors
07 April 2020 - 6:39AM
Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Susan
Steele has been appointed to the Company’s Board of Directors as a
Class III director, effective April 6, 2020 and will join the
Compensation Committee upon the conclusion of the upcoming 2020
Annual Meeting of Stockholders. With the addition of Ms. Steele,
the Board is now comprised of seven members, six of whom are
independent.
In conjunction with Ms. Steele’s appointment to
the Board, Engine Capital, L.P. has withdrawn its notice of its
intention to nominate director candidates at the 2020 Annual
Meeting and agreed to vote its shares in favor of the director
candidates nominated by the Company for election at such
meeting.
“We are pleased to welcome Susan to the Board
and look forward to working with her as we continue to focus on
executing the turnaround at the Company and creating a profitable
growth platform to maximize value for our shareholders,” said Jim
Green, President and CEO of Harvard Bioscience. Green added, “I
want to thank Engine Capital for its collaborative approach in
working with us, and our concentration is 100 percent on working
through today’s COVID-19 related challenges and preparing for a
much stronger business.”
“We appreciate the engagement we have had with
Jim and the Board and believe that Harvard Bioscience is
well-positioned to drive exceptional value in these turbulent
times,” said Arnaud Ajdler, Managing Member of Engine Capital.
Biography of Susan Steele
Ms. Steele is the Chief Executive Officer of
Steele & Partners LLC, a consulting firm specializing in
program management and supply chain performance, and sits on the
Board of Hill International (NYSE: HIL). She has more than 35 years
of experience leading global businesses in the A/E/C industry.
Previously, Ms. Steele served as Senior Vice President of Global
Supply Management at Jacobs Engineering, where she was responsible
for the company’s worldwide supply chain, leading a management team
of 1,600 people worldwide, with annual spending of $5 billion.
Prior to that, she worked for CH2M Hill as Vice President of
Business Development and Vice President, Manufacturing & Life
Sciences. She also served as the Program Director for the MASDAR
development program in the UAE. Ms. Steele holds a Masters of
Business Administration from the University of Miami, FL, and a
Bachelor of Science from Auburn University, AL. Ms. Steele is
affiliated with the Construction Industry Institute (CII) Board of
Advisors and Executive Committee, the EPC Procurement Executives
Group, and the Society for Maintenance & Reliability.
About Harvard Bioscience
Harvard Bioscience is a leading developer,
manufacturer and seller of technologies, products and services that
enable fundamental research, discovery, and pre-clinical testing
for drug development. Our customers range from renowned academic
institutions and government laboratories, to the world’s leading
pharmaceutical, biotechnology and clinical research organizations.
With operations in North America and Europe, we sell
through a combination of direct and distribution channels to
customers around the world. For more information, please visit our
website at www.harvardbioscience.com.
Investor
ContactMichael RossiChief Financial Officer(508)
893-8999mrossi@harvardbioscience.com
OR
Okapi Partners
LLCBruce Goldfarb / Chuck Garske / Lisa Patel(212)
297-0720info@okapipartners.com
Media
ContactSloane & CompanyDan Zacchei / Joe
Germanidzacchei@sloanepr.com / jgermani@sloanepr.com
Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From Aug 2023 to Aug 2024